Corcept Flags Direct Revenue Hit as IRA Pricing Rules Widen
Corcept Therapeutics told investors the Inflation Reduction Act's inflation rebates may materially cut its revenue and profits in 2026 and beyond, one of the sharpest company-specific warnings in a filing season otherwise dominated by boilerplate recitations of the same 2022 law.
Corcept Therapeutics Inc. (CORT), the maker of hypercortisolism treatments, told investors that the Inflation Reduction Act's Medicare Part D inflation rebate provision "may materially reduce our revenue and profits in 2026 and beyond". That is a more direct financial forecast than most peers attached to the same law, and it came paired with a carve-out: Corcept said its Hypercortisolism Products qualify as orphan drugs indicated for a single rare disease, which exempts them from the Medicare price negotiation program, alongside any drug with less than $200 million in annual Medicare expenditures. The company still faces the inflation rebate, which it noted applies to any medication sold to Medicare recipients whether or not that drug is subject to price negotiation.
Most other companies in this window described the same law in near-identical language lifted from prior years' filings. Edgewise Therapeutics, Inc. (EWTX), a muscle-disease biotech; Forte Biosciences, Inc. (FBRX); Vera Therapeutics, Inc. (VERA); SpyGlass Pharma, Inc. (SGP); Gossamer Bio, Inc. (GOSS); LENZ Therapeutics, Inc. (LENZ); and Enliven Therapeutics, Inc. (ELVN) each recited that the IRA lets the federal government negotiate a maximum fair price for high-cost, single-source Medicare drugs, penalizes noncompliant manufacturers with an excise tax, and requires inflation rebates across Medicare Part B and Part D. Rhythm Pharmaceuticals, Inc. (RYTM), which markets obesity-related therapies, called the IRA "the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010".
Where the disclosures moved was in the specificity of the negotiation rollout. Edgewise's August filing said CMS had selected 10 high-cost Medicare Part D drugs for 2026, with negotiated maximum fair prices already announced; 15 additional drugs selected for 2027; and up to 15 more for 2028 that may be covered under either Part B or Part D, with up to 20 more added each year after 2029. Vera and Gossamer echoed that CMS had published negotiated prices for the initial 10 drugs effective in 2026 and the subsequent 15 effective in 2027, with Gossamer adding that HHS had already published the next set of 15 drugs slated for negotiation. Gilead Sciences, Inc. (GILD), the antiviral and virology drugmaker, laid out the same phase-in schedule and noted that the negotiated Medicare prices could also pull down the Medicaid Best Price and the 340B ceiling price for covered entities, along with the Average Sales Price used for Part B reimbursement.
Litigation risk hardened into a standing feature of the disclosure rather than a footnote. Edgewise stated that "various industry stakeholders have initiated lawsuits against the federal government asserting that the price negotiation provisions of the Inflation Reduction Act are unconstitutional". Vera and Gossamer both flagged that the negotiation program remains subject to ongoing legal challenges even as CMS continues to implement it through guidance rather than formal regulation.
A second and newer thread surfaced in this window: disclosures naming the One Big Beautiful Bill Act, signed into law in July 2025. Gossamer said the law imposes "significant reductions in the funding of the Medicaid program". LENZ described the same act as introducing Medicaid cuts alongside new participant work and eligibility requirements that will "significantly change the administration and applicability of" Medicaid coverage. Neither company had cited this law in earlier disclosure cycles, marking a fresh line item layered on top of the IRA's Medicare provisions.
Executive-branch action on pricing also entered the record. LENZ disclosed that the current administration issued orders directing the Secretary of Health and Human Services to build a mechanism for patients to buy drugs directly from manufacturers at a most-favored-nation price and directing trade officials to act against foreign countries accused of undercutting U.S. drug prices. Forte separately flagged the risk from "government agreements with pharmaceutical companies and other government measures that use most-favored-nation pricing targets," including international reference pricing, and said it could not predict the full impact of executive orders aimed at cutting drug prices or reshoring manufacturing.
Corcept's own recitation of the negotiation mechanics was among the most granular in the group. It specified that a drug must be on the market for at least seven years without generic competition to be eligible, that orphan single-indication drugs and those with under $200 million in annual Medicare spending are exempt, and that only Part D drugs are eligible for the program's first two years, 2026 and 2027. It also detailed the enforcement backstop: manufacturers that decline to negotiate or refuse to sell at the published Maximum Fair Price face civil money penalties or excise tax liability on sales of that drug.
Taken together, the disclosures describe a program moving from statutory description to operating reality. CMS has now published negotiated prices for two waves of drugs and named a third, litigation over the program's constitutionality continues, and two additional statutes — the One Big Beautiful Bill Act and pending most-favored-nation executive orders — are starting to appear in disclosure language alongside the original IRA text. Corcept's explicit revenue warning, paired with its orphan-drug exemption, is the clearest indicator in this set of how unevenly that operating reality is expected to land across the group.